Quarterly report pursuant to Section 13 or 15(d)

Consolidated Balance Sheets (Unaudited)

v3.10.0.1
Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Jun. 30, 2018
Dec. 31, 2017
Current assets:    
Cash and cash equivalents [note 6] $ 15,280 $ 5,284
Restricted cash [note 6 and note 9]   222
Amounts receivable 124 9
Prepaid expenses 168 393
Total current assets 15,572 5,908
Restricted cash [note 6] 50 50
Property and equipment, net 42 59
Other assets 101 309
License agreement [note 2, 4 and 5] 2,421 2,532
Goodwill [note 2 and 5] 1,034 1,034
Total assets 19,220 9,892
Current liabilities:    
Accounts payable 251 213
Accrued liabilities other 966 438
Accrued clinical liabilities 782 877
Accrued compensation 750 458
Current portion of long-term obligations [note 9] 11 27
Total current liabilities 2,760 2,013
Long-term obligations, less current portion [note 9] 18  
Total liabilities 2,778 2,013
Commitments and contingencies [note 9]
Stockholders' equity:    
Series A convertible preferred stock, $0.001 par value, 5,000,000 shares authorized, 3,283 issued and outstanding at June 30, 2018 and zero issued and outstanding at December 31, 2017.
Common stock, $0.001 par value, 150,000,000 shares authorized, 4,238,526 and 1,195,675 issued at June 30, 2018 and December 31, 2017, respectively, and 4,238,526 and 1,194,793 outstanding at June 30, 2018 and December 31, 2017, respectively. 15 12
Additional paid-in capital 34,926 20,556
Accumulated deficit (18,504) (12,694)
Accumulated other comprehensive income 5 5
Total stockholders' equity 16,442 7,879
Total liabilities and stockholders' equity $ 19,220 $ 9,892